10mg Tirzepatide Dosage: Is It the Right Step for You?

What the titration schedule looks like by the time you reach 10mg

Mounjaro's licensed schedule starts at 2.5mg, a dose that exists specifically to settle your system, not to produce the weight loss you're aiming for. From there, treatment steps upward through 5mg and 7.5mg at roughly four-week intervals, subject to how you're tolerating each stage. By the time 10mg is on the table, you're typically three months in, and the earlier doses will have given your prescriber real evidence about how your body responds to tirzepatide.

That history matters. A smooth run at 7.5mg (appetite down, no significant nausea, injection sites fine) is a reasonable signal that 10mg is appropriate. A rougher experience might mean staying put for another month before stepping up. The full tirzepatide dosage overview covers how the schedule is meant to work at each stage, and it's a useful reference if you want to understand where 10mg sits in the wider picture.

One practical note many patients don't consider: the 10mg KwikPen goes into the fridge alongside the rest of your supply. Keep it in the door rather than the back of the shelf, temperature at the rear can fluctuate more than you'd expect. Always check the Patient Information Leaflet for the exact storage instructions; the window for room-temperature use is specified there, and your prescriber can't set it for you.

What changes (and what doesn't) at the tirzepatide 10mg dosage

The mechanism doesn't change. Tirzepatide is a dual GIP and GLP-1 receptor agonist at every strength, acting on two gut-hormone pathways simultaneously to reduce appetite and slow gastric emptying. What the higher dose does is intensify that effect: more receptor activation, stronger appetite suppression, typically greater weight reduction over time. That's the upside.

The tradeoff is that gastrointestinal side effects (nausea, loose stools, reflux, a general sense of sluggishness in the first day or two after injecting) can return briefly when the dose increases, even if they'd largely resolved at 7.5mg. Most people find these settle within one to two weeks. If they don't, or if they're severe, that's a conversation for your prescriber, not something to push through alone.

Clinical trial data published in the SURMOUNT-1 paper in the New England Journal of Medicine showed average weight reductions of around 20–21% at the 15mg maintenance dose over 72 weeks. The 10mg dose isn't the destination for everyone (some people respond so well they don't need to go further) but for many it's a step on the way to a higher maintenance. Whether 10mg becomes your long-term dose is something your prescriber determines through ongoing clinical review, and our tirzepatide 10mg dosage chart can help you follow how the numbers map out across the schedule.

The factors your prescriber weighs before approving this step

A move to tirzepatide 10mg dosage isn't simply a function of having been on the lower dose for four weeks. Prescribers look at several things together: your current weight trajectory, how well you've tolerated 7.5mg, any new health information, and whether the dose you're on is still producing meaningful change. If weight loss has stalled noticeably at 7.5mg and you've tolerated it without significant problems, stepping to 10mg is a logical clinical decision. If things are going well and your progress is on track, staying at 7.5mg for longer might be the right call.

This is why clinical re-review at every repeat matters. A prescriber who simply renews a supply without looking at your current position isn't meeting the standard of care these medicines require. At nume, a real clinician (not an automated system) reviews your repeat before anything is dispatched. Our clinical team's approach is built around that kind of ongoing oversight, not a one-time assessment at onboarding.

If you're in the middle of this decision now, or approaching the 7.5mg-to-10mg transition, you can read about what to expect at the tirzepatide 10 mg dosage to get a clearer picture of what the schedule looks like in practice. And if you're not yet on treatment but wondering whether Mounjaro is appropriate for you, our free consultation page is the starting point, a prescriber will assess your eligibility properly, without any assumptions about which dose you'll end up on.

Eligibility and what the private route looks like from here

Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea and cardiovascular disease are the most common examples. NICE's appraisal of tirzepatide (TA1026) sets out the criteria for NHS eligibility, which are narrower and phased over time. Private treatment through a regulated online pharmacy sits alongside the NHS route for people who don't meet the current NHS criteria or who prefer not to wait.

For context on what private treatment costs at different doses (10mg included) the Mounjaro cost page sets out what's typically involved and what a legitimate price should include. That's worth reading before you compare providers, because a low headline figure doesn't always mean an affordable outcome once prescription fees, delivery and clinical support are factored in. It can also help to understand how tirzepatide 5 mg dosage fits into the earlier stages of treatment, particularly if you're weighing up the full cost of the titration journey from the start.

If you're already on treatment through another provider and looking to continue or step up, a transfer is possible subject to clinical review. The Mounjaro overview covers the broader picture (how it works, what to expect, and who it's for) if you want to read around the subject before starting your consultation.